A Comparison of Performance of the Different Generations of Magnesium-Based Bioresorbable Coronary Stents
Journal of Clinical Medicine · 26.06.2026 · 15 (13) · 5003
DOI: 10.3390/jcm15135003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.06.2026. Verfasst von Jeremy Ang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Services, Townsville University Hospital, Townsville, QLD 4814, Australia. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The permanence of contemporary coronary stents is associated with chronic complications, particularly in-stent restenosis and stent thrombosis. Poly-L-lactic-acid-based bioresorbable stents were withdrawn given late stent thrombosis risk. Magnesium-based bioresorbable stents (MgBRS) have emerged as promising alternatives. This study documents the safety and efficacy profile of MgBRS generations.
Methods
A systematic review was performed using EMBASE, MEDLINE and Web of Science (2007 to August 2025). Studies include individuals requiring percutaneous coronary intervention for coronary artery disease with MgBRS. Primary outcomes were cardiac death, definite/probable scaffold thrombosis and target vessel failure (TVF), organised into ≤12, ≤24, ≤36 and ≤60 months. The secondary outcome was late lumen loss (LLL).
Results
Four MgBRS generations were identified: AMS-1, DREAMS 1G, Magmaris and Freesolve; and 25 studies were included. Cardiac death and stent thrombosis rates were under 1.0% up to 24 months for all, and 0% with Freesolve at 36 months. AMS-1 had the highest TVF rate at 44.4% at 12 months, improving to 3.6% at 36 months in Freesolve. Only Magmaris had 60-month data, showing 3.4% cardiac death, 2.7% stent thrombosis and 16.4% TVF rates. The data suggest improvement in 12-month LLL: DREAMS 1G (0.4 ± 0.3 mm), Magmaris (0.5 ± 1.1 mm) and Freesolve (0.2 ± 0.4 mm).
Conclusions
Each successive generation demonstrated improvement in all studied outcomes since the underperformance of AMS-1. The favourable performance of Freesolve is comparable to contemporary drug-eluting stents. Results of randomised head-to-head trials are anticipated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiac Services, Townsville University Hospital, Townsville, QLD 4814, Australia.
- Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia.
- Eastern Heart Clinic, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
- MRC Clinical Trials Unit, University College London, London WC1V 6LJ, UK.
ORCID-Profile: Jeremy Ang, Liam Marsden Back
Zitieren
APA
Ang, J., & Back, L. M. (2026). A Comparison of Performance of the Different Generations of Magnesium-Based Bioresorbable Coronary Stents. Journal of Clinical Medicine, 15(13), 5003. https://doi.org/10.3390/jcm15135003
Vancouver
Ang J, Back LM. A Comparison of Performance of the Different Generations of Magnesium-Based Bioresorbable Coronary Stents. Journal of Clinical Medicine. 2026;15(13):5003. doi:10.3390/jcm15135003
BibTeX
@article{Ang2026,
author = {Ang, Jeremy and Back, Liam Marsden},
title = {A Comparison of Performance of the Different Generations of Magnesium-Based Bioresorbable Coronary Stents},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {5003},
doi = {10.3390/jcm15135003}
}
EUVIMED